Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation”

M.B.B. Foote; J. Li; D.S. Tan; P.A. Calvo Ferrandiz; Rachel Galot; Elena Garralda; Tormod Kyrre Guren; Antoîne Italiano; C.-C. Lin; Z.A. Wainberg; Jeffrey Yachnin; T.A. Yap; Ruben de Kanter; N. Grande; Aude Izaac; D. Jankovic; Laurent Sansregret; C. Zhang; A.K. Nagaraja; Yasutoshi Kuboki

doi:10.1016/j.annonc.2026.01.001

Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation”

Annals of Oncology 2026

View at publisher

Authors: M.B.B. Foote, J. Li, D.S. Tan, P.A. Calvo Ferrandiz, Rachel Galot, Elena Garralda, Tormod Kyrre Guren, Antoîne Italiano, C.-C. Lin, Z.A. Wainberg, Jeffrey Yachnin, T.A. Yap

+8 more

Ruben de Kanter, N. Grande, Aude Izaac, D. Jankovic, Laurent Sansregret, C. Zhang, A.K. Nagaraja, Yasutoshi Kuboki

DOI: 10.1016/j.annonc.2026.01.001

Cited by: 0

Fields of Study & Subjects

Genetic factors in colorectal cancer Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

Publication details

Journal / source: Annals of Oncology
Publication date: 1 February 2026
Language: EN